YU53502A - Blokada aksonalnog rasta posredstvom nogo receptora - Google Patents
Blokada aksonalnog rasta posredstvom nogo receptoraInfo
- Publication number
- YU53502A YU53502A YU53502A YUP53502A YU53502A YU 53502 A YU53502 A YU 53502A YU 53502 A YU53502 A YU 53502A YU P53502 A YUP53502 A YU P53502A YU 53502 A YU53502 A YU 53502A
- Authority
- YU
- Yugoslavia
- Prior art keywords
- nogo
- nogo receptor
- disclosed
- axonal growth
- mediated blockade
- Prior art date
Links
- 102000005781 Nogo Receptor Human genes 0.000 title abstract 3
- 108020003872 Nogo receptor Proteins 0.000 title abstract 3
- 230000003376 axonal effect Effects 0.000 title abstract 2
- 230000001404 mediated effect Effects 0.000 title abstract 2
- 102000010410 Nogo Proteins Human genes 0.000 abstract 3
- 108010077641 Nogo Proteins Proteins 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 2
- 208000016192 Demyelinating disease Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 230000002490 cerebral effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 208000020431 spinal cord injury Diseases 0.000 abstract 1
- 230000008733 trauma Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5058—Neurological cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/285—Demyelinating diseases; Multipel sclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17570700P | 2000-01-12 | 2000-01-12 | |
| US20736600P | 2000-05-26 | 2000-05-26 | |
| US23637800P | 2000-09-29 | 2000-09-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| YU53502A true YU53502A (sh) | 2005-11-28 |
Family
ID=27390581
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| YU53502A YU53502A (sh) | 2000-01-12 | 2001-01-12 | Blokada aksonalnog rasta posredstvom nogo receptora |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US20020012965A1 (https=) |
| EP (2) | EP2163561A1 (https=) |
| JP (1) | JP4763207B2 (https=) |
| KR (1) | KR100828058B1 (https=) |
| CN (1) | CN100354307C (https=) |
| AT (1) | ATE466882T1 (https=) |
| AU (1) | AU784349C (https=) |
| BG (1) | BG106907A (https=) |
| BR (1) | BR0107613A (https=) |
| CA (1) | CA2397199C (https=) |
| CZ (1) | CZ20022438A3 (https=) |
| DE (1) | DE60142023D1 (https=) |
| EA (1) | EA008480B1 (https=) |
| EE (1) | EE200200386A (https=) |
| ES (1) | ES2341842T3 (https=) |
| GE (1) | GEP20063830B (https=) |
| HK (1) | HK1051543A1 (https=) |
| HU (1) | HUP0203863A3 (https=) |
| IL (2) | IL150566A0 (https=) |
| IS (1) | IS6455A (https=) |
| MX (1) | MXPA02006885A (https=) |
| NO (1) | NO20023387L (https=) |
| NZ (2) | NZ520065A (https=) |
| PL (1) | PL356887A1 (https=) |
| SK (1) | SK9992002A3 (https=) |
| WO (1) | WO2001051520A2 (https=) |
| YU (1) | YU53502A (https=) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999066041A1 (en) | 1998-06-16 | 1999-12-23 | Human Genome Sciences, Inc. | 94 human secreted proteins |
| US7723488B2 (en) | 1998-03-27 | 2010-05-25 | Genentech, Inc. | Monoclonal antibodies to secreted and transmembrane polypeptides |
| US7371836B2 (en) | 1998-03-27 | 2008-05-13 | Genentech, Inc. | PRO526 nucleic acids |
| US20020072493A1 (en) * | 1998-05-19 | 2002-06-13 | Yeda Research And Development Co. Ltd. | Activated T cells, nervous system-specific antigens and their uses |
| US7034132B2 (en) | 2001-06-04 | 2006-04-25 | Anderson David W | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| IL150566A0 (en) * | 2000-01-12 | 2003-02-12 | Univ Yale | Nucleic acids and polypeptides and nogo-receptor proteins |
| US7119165B2 (en) * | 2000-01-12 | 2006-10-10 | Yale University | Nogo receptor-mediated blockade of axonal growth |
| WO2002081628A2 (en) * | 2001-04-05 | 2002-10-17 | Ribozyme Pharmaceuticals, Incorporated | Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies |
| NZ525422A (en) | 2000-10-06 | 2006-09-29 | Biogen Idec Inc | Isolated polynucleotides comprising a nucleic acid which encodes a polypeptide which modulates axonal growth in CNS neurons |
| GB0101313D0 (en) * | 2001-01-18 | 2001-02-28 | Glaxo Group Ltd | Assay |
| GB0101312D0 (en) | 2001-01-18 | 2001-02-28 | Glaxo Group Ltd | Assay |
| JP2005507246A (ja) * | 2001-08-27 | 2005-03-17 | ノバルティス アクチエンゲゼルシャフト | Ｎｏｇｏレセプターホモログおよびそれらの使用 |
| US7309485B2 (en) * | 2001-12-03 | 2007-12-18 | Children's Medical Center Corporation | Reducing myelin-mediated inhibition of axon regeneration |
| FR2841261B1 (fr) * | 2002-06-25 | 2004-08-27 | Univ Pasteur | Compositions et methodes pour detecter les pathologies affectant la transmission neuromusculaire |
| EP1534736B1 (en) * | 2002-08-10 | 2010-06-02 | Yale University | Nogo receptor antagonists |
| PT1534736E (pt) | 2002-08-10 | 2010-09-07 | Univ Yale | Antagonistas do receptor nogo |
| GB0228832D0 (en) | 2002-12-10 | 2003-01-15 | Novartis Ag | Organic compound |
| CN1745094A (zh) * | 2002-12-06 | 2006-03-08 | 新加坡综合医院有限公司 | 肽,其抗体,以及它们在中枢神经系统损伤的治疗中的用途 |
| US7842666B2 (en) * | 2002-12-20 | 2010-11-30 | Research Foundation Of City University Of New York | Inhibitors of myelin-associated glycoprotein (MAG) activity for regulating neural growth and regeneration |
| WO2004085648A2 (en) | 2003-03-19 | 2004-10-07 | Biogen Idec Ma Inc. | Nogo receptor binding protein |
| US7541335B2 (en) | 2003-04-04 | 2009-06-02 | University Of Rochester | Nogo-receptors and methods of use |
| EP1615654A2 (en) * | 2003-04-16 | 2006-01-18 | Yale University | Nogo-receptor antagonists for the treatment of conditions involving amyloid plaques |
| AU2004247018A1 (en) * | 2003-05-15 | 2004-12-23 | Bayhill Therapeutics, Inc. | Novel immunomodulating peptide |
| EP3514238B1 (en) * | 2003-05-16 | 2021-05-05 | Acorda Therapeutics, Inc. | Proteoglycan degrading mutants for treatment of cns |
| US7959914B2 (en) | 2003-05-16 | 2011-06-14 | Acorda Therapeutics, Inc. | Methods of reducing extravasation of inflammatory cells |
| GB0321997D0 (en) * | 2003-09-19 | 2003-10-22 | Novartis Ag | Organic compound |
| WO2005059515A2 (en) * | 2003-12-16 | 2005-06-30 | Children's Medical Center Corporation | Method for treating neurological disorders |
| US8912144B2 (en) * | 2003-12-16 | 2014-12-16 | Children's Medical Center Corporation | Method for treating stroke via administration of NEP1-40 and inosine |
| PT1776136E (pt) | 2004-06-24 | 2012-12-05 | Biogen Idec Inc | Tratamento de estados que envolvem desmielinização |
| CA2576193A1 (en) | 2004-08-03 | 2006-02-16 | Biogen Idec Ma Inc. | Taj in neuronal function |
| WO2006047049A2 (en) * | 2004-10-01 | 2006-05-04 | Yale University | Nogo-a polypeptide fragments, variant nogo receptor-1 polypeptides, and uses thereof |
| US20090137484A1 (en) * | 2004-12-01 | 2009-05-28 | National University Of Singapore | Neuronal Network-Interacting Peptide |
| US7893032B2 (en) | 2005-07-07 | 2011-02-22 | Yale University | NgR variants and compositions thereof for suppressing axonal growth inhibition |
| SI1904104T1 (sl) | 2005-07-08 | 2013-12-31 | Biogen Idec Ma Inc. | Protitelesa SP35 in njihova uporaba |
| JP5189985B2 (ja) | 2005-09-26 | 2013-04-24 | アコーダ セラピューティクス、インク． | コンドロイチナーゼａｂｃｉ変異体を用いた組成物およびその使用方法 |
| CA2913655A1 (en) | 2006-01-27 | 2007-08-09 | Biogen Ma Inc. | Nogo receptor antagonists |
| JP2009538282A (ja) * | 2006-05-15 | 2009-11-05 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 乏突起膠細胞の生存を促進させるためのＮｏｇｏ受容体−１（ＮｇＲ１）アンタゴニストの使用 |
| JP2009544703A (ja) | 2006-07-24 | 2009-12-17 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Ｓｐ３５またはＴｒｋＡアンタゴニストの投与により髄鞘形成、ニューロンの生存および希乏突起膠細胞の分化を促進するための方法 |
| MX2009005361A (es) | 2006-11-21 | 2009-06-05 | Abbott Lab | Anticuerpos monoclonales neutralizantes contra el receptor de nogo-66 (ngr) y usos de los mismos. |
| EP2276500A4 (en) | 2008-03-13 | 2015-03-04 | Univ Yale | REACTIVATION OF AXON GROWTH AND AXON RECOVERY IN CHRONIC REVERSE MARKET INJURIES |
| CL2009001155A1 (es) * | 2008-05-13 | 2010-06-04 | Genentech Inc | Anticuerpo anti-pirb/lilrb aislado; polinucleotido que lo codifica; vector; celula huesped; metodo de obtencion; composicion farmaceutica que lo comprende; kit; y su uso para tratar enfermedades neurodegenerativas. |
| DK2982695T3 (da) | 2008-07-09 | 2019-05-13 | Biogen Ma Inc | Sammensætninger, der omfatter antistoffer mod lingo eller fragmenter deraf |
| CN104470541A (zh) | 2012-05-14 | 2015-03-25 | 比奥根艾迪克Ma公司 | 用于治疗涉及运动神经元的疾患的lingo-2拮抗剂 |
| CN104935294B (zh) * | 2014-03-20 | 2018-07-20 | 晶宏半导体股份有限公司 | 振荡器 |
| JP2018504400A (ja) | 2015-01-08 | 2018-02-15 | バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． | Ｌｉｎｇｏ‐１拮抗薬及び脱髄障害の治療のための使用 |
| CN105061560B (zh) * | 2015-07-17 | 2018-10-09 | 暨南大学 | 一种Nogo-A受体结合肽及其衍生物与应用 |
| CN113527462B (zh) * | 2020-04-22 | 2023-05-23 | 北京大学 | 一种具有镇痛作用的小分子肽及其特异性抗体 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4736866B1 (en) | 1984-06-22 | 1988-04-12 | Transgenic non-human mammals | |
| US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| US4839288A (en) | 1986-01-22 | 1989-06-13 | Institut Pasteur | Retrovirus capable of causing AIDS, antigens obtained from this retrovirus and corresponding antibodies and their application for diagnostic purposes |
| US5466585A (en) | 1986-04-15 | 1995-11-14 | Ciba-Geigy Corporation | Interferon-induced human protein in pure form, monoclonal antibodies thereto, and test kits containing these antibodies |
| US4861719A (en) | 1986-04-25 | 1989-08-29 | Fred Hutchinson Cancer Research Center | DNA constructs for retrovirus packaging cell lines |
| CA1315719C (en) | 1988-02-05 | 1993-04-06 | Arthur Bank | Retroviral packaging cell lines and processes of using same |
| CA1339354C (en) | 1988-09-01 | 1997-08-26 | The Whitehead Institute For Biomedical Research | Recombinant retroviruses with amphotropic and ecotropic host ranges |
| CA1341050C (en) | 1988-11-04 | 2000-07-11 | Martin E. Schwab | Neurite growth regulatory factors |
| DE68923362T2 (de) | 1988-11-04 | 1996-03-28 | Zuerich Erziehungsdirektion | Wachstumsregelfaktoren für neuriten. |
| US5250414A (en) | 1988-11-04 | 1993-10-05 | Erziehungsdirektion Of The Canton Zurich | Diagnostic methods using neurite growth regulatory factors |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5723719A (en) | 1991-08-08 | 1998-03-03 | Health Research Inc. | Transgenic mouse as model for diseases involving dopaminergic dysfunction |
| DE4126968A1 (de) | 1991-08-14 | 1993-02-18 | Detlev Prof Dr Med Ganten | Transgene ratten, die in ihrem genom mindestens ein menschliches gen enthalten, das an der blutdruckregulation beteiligt ist |
| ATE273386T1 (de) | 1991-09-20 | 2004-08-15 | Hutchinson Fred Cancer Res | Menschliches cyclin e |
| EP0620849B1 (en) | 1992-01-07 | 2003-06-25 | Elan Pharmaceuticals, Inc. | Transgenic animal models for alzheimer's disease |
| US5733720A (en) | 1992-06-18 | 1998-03-31 | Washington University | Genetically engineered cell lines for detecting infectious herpesvirus and methods therefor |
| US5602307A (en) | 1992-08-12 | 1997-02-11 | Baylor College Of Medicine | Non-human animal having predefined allele of a cellular adhesion gene |
| US5731490A (en) | 1992-09-29 | 1998-03-24 | The Ontario Cancer Institute | Mutant mouse lacking the expression of interferon regulatory factor 1 (IRF-1) |
| WO1994017831A1 (en) | 1993-02-11 | 1994-08-18 | Erziehungsdirektion Of The Canton Zurich | A combination of neurotrophin and antibody directed toward myelin-associated neurite growth inhibitory protein promotes central nervous system regeneration |
| FR2705361B1 (fr) | 1993-05-18 | 1995-08-04 | Centre Nat Rech Scient | Vecteurs viraux et utilisation en thérapie génique. |
| DK75393D0 (da) | 1993-06-24 | 1993-06-24 | Symbicom Ab | Production of protein |
| ATE424927T1 (de) | 1993-10-28 | 2009-03-15 | Houston Advanced Res Ct | Mikrofabriziertes poröses durchflussgerät zur diskreten bestimmung von bindungsreaktionen |
| MX198456B (es) | 1994-03-09 | 2000-09-05 | Abbott Lab | Animales trangenicos que producen oligosacaridos y glucoconjugados. |
| FR2718329B1 (fr) | 1994-03-21 | 2002-09-20 | Rhone Poulenc Rorer Sa | Lapin transgénique sensibilisé aux dyslipoprotéinémies. |
| US5908969A (en) | 1994-05-13 | 1999-06-01 | The Regents Of The University Of California | Method of detecting prions in a sample and transgenic animal used for same |
| WO2000073452A2 (en) * | 1999-06-02 | 2000-12-07 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| US5728915A (en) | 1995-05-08 | 1998-03-17 | Children's Hospital, Inc. | Transgenic mice which express simian SV 40 T-antigen under control of the retinoblastoma gene promoter |
| US5763263A (en) | 1995-11-27 | 1998-06-09 | Dehlinger; Peter J. | Method and apparatus for producing position addressable combinatorial libraries |
| US5961976A (en) | 1996-06-03 | 1999-10-05 | United Biomedical, Inc. | Antibodies against a host cell antigen complex for pre- and post-exposure protection from infection by HIV |
| US5858708A (en) | 1996-08-12 | 1999-01-12 | Bandman; Olga | Polynucleotides encoding two novel human neuroendocrine-specific proteins |
| WO2000053756A2 (en) * | 1999-03-08 | 2000-09-14 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| WO1999066041A1 (en) * | 1998-06-16 | 1999-12-23 | Human Genome Sciences, Inc. | 94 human secreted proteins |
| WO2000070050A1 (en) * | 1999-05-14 | 2000-11-23 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| CA2311640A1 (en) * | 1997-12-03 | 1999-06-10 | Genentech, Inc. | Polypeptides and nucleic acids encoding the same |
| JP3868740B2 (ja) * | 1998-03-10 | 2007-01-17 | ジェネンテック・インコーポレーテッド | 新規なポリペプチド及びそれをコードする核酸 |
| AU762055B2 (en) * | 1998-03-10 | 2003-06-19 | Genentech Inc. | Novel polypeptides and nucleic acids encoding the same |
| AU3134799A (en) | 1998-04-16 | 1999-11-08 | Peter Erich Braun | Nevron growth inhibitory molecules or derivatives thereof used to immunize mammals thereby promoting axon regeneration |
| CA2324297A1 (en) * | 1998-04-23 | 1999-10-28 | Genentech, Inc. | Sh2 domain-containing peptides |
| CA2326001A1 (en) * | 1998-04-24 | 1999-11-04 | Genentech, Inc. | Fizz proteins |
| AU761340B2 (en) * | 1998-06-02 | 2003-06-05 | Genentech Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| CZ304224B6 (cs) * | 1998-11-06 | 2014-01-15 | Schwab | Monoklonální protilátka |
| KR100529270B1 (ko) * | 1998-12-01 | 2005-11-21 | 제넨테크, 인크. | 혈관신생 및 심혈관형성의 촉진 또는 억제 |
| JP3993746B2 (ja) * | 1998-12-22 | 2007-10-17 | ジェネンテック・インコーポレーテッド | 腫瘍性細胞成長阻害のための組成物及び方法 |
| CA2362427A1 (en) * | 1999-03-08 | 2000-09-14 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| CA2383592A1 (en) * | 1999-03-31 | 2000-10-05 | Curagen Corporation | 2384891 acids including open reading frames encoding polypeptides; orfx |
| WO2001009162A2 (en) * | 1999-07-30 | 2001-02-08 | Millennium Pharmaceuticals, Inc. | Secreted proteins and uses thereof |
| IL150566A0 (en) * | 2000-01-12 | 2003-02-12 | Univ Yale | Nucleic acids and polypeptides and nogo-receptor proteins |
-
2001
- 2001-01-12 IL IL15056601A patent/IL150566A0/xx active IP Right Grant
- 2001-01-12 WO PCT/US2001/001041 patent/WO2001051520A2/en not_active Ceased
- 2001-01-12 EA EA200200755A patent/EA008480B1/ru not_active IP Right Cessation
- 2001-01-12 KR KR1020027008912A patent/KR100828058B1/ko not_active Expired - Fee Related
- 2001-01-12 EE EEP200200386A patent/EE200200386A/xx unknown
- 2001-01-12 DE DE60142023T patent/DE60142023D1/de not_active Expired - Lifetime
- 2001-01-12 CA CA2397199A patent/CA2397199C/en not_active Expired - Fee Related
- 2001-01-12 NZ NZ520065A patent/NZ520065A/en unknown
- 2001-01-12 AT AT01942367T patent/ATE466882T1/de not_active IP Right Cessation
- 2001-01-12 BR BR0107613-2A patent/BR0107613A/pt not_active IP Right Cessation
- 2001-01-12 HK HK03102060.8A patent/HK1051543A1/zh unknown
- 2001-01-12 SK SK999-2002A patent/SK9992002A3/sk unknown
- 2001-01-12 PL PL01356887A patent/PL356887A1/xx unknown
- 2001-01-12 AU AU29401/01A patent/AU784349C/en not_active Ceased
- 2001-01-12 GE GE4901A patent/GEP20063830B/en unknown
- 2001-01-12 CZ CZ20022438A patent/CZ20022438A3/cs unknown
- 2001-01-12 US US09/758,140 patent/US20020012965A1/en not_active Abandoned
- 2001-01-12 NZ NZ541694A patent/NZ541694A/en unknown
- 2001-01-12 ES ES01942367T patent/ES2341842T3/es not_active Expired - Lifetime
- 2001-01-12 EP EP09170776A patent/EP2163561A1/en not_active Withdrawn
- 2001-01-12 YU YU53502A patent/YU53502A/sh unknown
- 2001-01-12 CN CNB018049400A patent/CN100354307C/zh not_active Expired - Fee Related
- 2001-01-12 EP EP01942367A patent/EP1248803B1/en not_active Expired - Lifetime
- 2001-01-12 JP JP2001551104A patent/JP4763207B2/ja not_active Expired - Fee Related
- 2001-01-12 HU HU0203863A patent/HUP0203863A3/hu unknown
- 2001-01-12 MX MXPA02006885A patent/MXPA02006885A/es not_active Application Discontinuation
-
2002
- 2002-07-03 IL IL150566A patent/IL150566A/en not_active IP Right Cessation
- 2002-07-03 IS IS6455A patent/IS6455A/is unknown
- 2002-07-05 BG BG106907A patent/BG106907A/bg unknown
- 2002-07-12 NO NO20023387A patent/NO20023387L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| YU53502A (sh) | Blokada aksonalnog rasta posredstvom nogo receptora | |
| WO2003031462A3 (en) | Nogo receptor-mediated blockade of axonal growth | |
| AU1153902A (en) | Nogo receptor homologs | |
| DE60028970D1 (de) | An her2 bindende peptidverbindungen | |
| SG157951A1 (en) | Cripto blocking antibodies and uses thereof | |
| EP2314617A3 (en) | ActRII receptor polypeptides | |
| MXPA05004225A (es) | Anticuerpos de neutralizacion contra gdf-8, y sus usos. | |
| AU1922101A (en) | Human fgf-21 gene and gene expression products | |
| IL125590A (en) | Peptide immunogens, process for their preparation and use thereof as vaccines against allergies | |
| WO2002044320A3 (en) | Human elongase genes and uses thereof | |
| AU6721998A (en) | Therapeutic use of the smr1 protein and active derivatives thereof | |
| HUP0402327A2 (hu) | Inzulinszerű növekedési faktort kötő 5-ös fehérje expressziójának antiszensz módosítása | |
| AU2001233912A1 (en) | Diagnosis of breast cancer using bcmp-81 as marker | |
| PL336897A1 (en) | Novel salts of bpc peptides, pharmaceutic compositions conatining them and method of obtaining such salts | |
| WO2003003988A3 (en) | Peptides which modulate blood coagulation and methods of use thereof | |
| WO2004067725A3 (en) | Methods of identifying modulators of nmur2-mediated activity | |
| WO2000042165A3 (en) | Bone marrow-specific protein | |
| WO1999046381A3 (en) | Human fgf gene and gene expression products | |
| UA32302A (uk) | Спосіб усунення післяопераційних деформацій м'яких тканин |